Robert D Schreiber
Overview
Explore the profile of Robert D Schreiber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
28132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Goedegebuure S, Chen M, Mishra R, Zhang F, Yu Y, et al.
Genome Med
. 2024 Nov;
16(1):131.
PMID: 39538331
Background: Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both...
2.
Sultan H, Takeuchi Y, Ward J, Sharma N, Liu T, Sukhov V, et al.
Nature
. 2024 Jul;
632(8023):182-191.
PMID: 39048822
CD4 T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses, other CD4 T cells have recently been implicated...
3.
Meng W, Takeuchi Y, Ward J, Sultan H, Arthur C, Mardis E, et al.
Cancer Immunol Res
. 2024 May;
12(8):988-1006.
PMID: 38768391
Cancer neoantigens have been shown to elicit cancer-specific T-cell responses and have garnered much attention for their roles in both spontaneous and therapeutically induced antitumor responses. Mass spectrometry (MS) profiling...
4.
Luccia B, Molgora M, Khantakova D, Jaeger N, Chang H, Czepielewski R, et al.
Sci Immunol
. 2024 May;
9(95):eadi5374.
PMID: 38758808
The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti-programmed cell death protein 1 (PD-1) immune checkpoint blockade. Reprogramming TAM by either blocking or deleting the macrophage receptor...
5.
Ramirez C, Becker-Hapak M, Singhal K, Russler-Germain D, Frenkel F, Barnell E, et al.
Blood Adv
. 2024 May;
8(15):4035-4049.
PMID: 38713894
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that "polyvalent" vaccines could be engineered for...
6.
Thisted T, Smith F, Mukherjee A, Kleschenko Y, Feng F, Jiang Z, et al.
Nat Commun
. 2024 Apr;
15(1):2917.
PMID: 38575562
VISTA, an inhibitory myeloid-T-cell checkpoint, holds promise as a target for cancer immunotherapy. However, its effective targeting has been impeded by issues such as rapid clearance and cytokine release syndrome...
7.
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Moynihan K, Kumar M, Sultan H, Pappas D, Park T, Chin S, et al.
Cancer Discov
. 2024 Apr;
14(7):1206-1225.
PMID: 38563906
IL2 signals pleiotropically on diverse cell types, some of which contribute to therapeutic activity against tumors, whereas others drive undesired activity, such as immunosuppression or toxicity. We explored the theory...
8.
Meng W, Schreiber R, Lichti C
Adv Immunol
. 2023 Dec;
160:1-36.
PMID: 38042584
The role of aberrantly expressed proteins in tumors in driving immune-mediated control of cancer has been well documented for more than five decades. Today, we know that both aberrantly expressed...
9.
He M, Roussak K, Ma F, Borcherding N, Garin V, White M, et al.
Science
. 2023 Feb;
379(6633):eabg2752.
PMID: 36795805
The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for antitumor responses and effective immune checkpoint blockade (ICB) therapy. Here, we show that human CD1cCD5 DCs...
10.
Yokoyama W, Murphy K, Schreiber R, Colonna M
Immunity
. 2023 Feb;
56(2):225-226.
PMID: 36792565
No abstract available.